Asset profile
ARD-101
Small molecule
Evidence outlook · lead readout
NCT05121441 · Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05121441: Participants were randomly assigned to drug or placebo, and body weight change is a recognized measure of benefit in obesity trials, but only the participant (not staff) was kept blind, just 20 people took part, split unevenly (14 vs 6), and the reported weight difference is small next to how much individual results varied, with no statistical test provided to say whether it is real.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.